Claim Ledger
38% answered
Did management answer the analysts?
12 analyst questions audited, 5 evaded or deflected.
View Claim Ledger →
Divi's Laboratories — Q1 FY25
Divis Labs reported a steady Q1 FY25 with consolidated revenue of INR 2,197 crore, up 18% YoY, and PAT of INR 430 crore, up 21% YoY.
bullish
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Divis Labs reported a steady Q1 FY25 with consolidated revenue of INR 2,197 crore, up 18% YoY, and PAT of INR 430 crore, up 21% YoY. Growth was driven by strong custom synthesis (49% of mix, up ~40% YoY) and stable generic demand despite pricing pressure on legacy products like naproxen. The company is advancing in peptides (GLP-1 fragments), contrast media, and new generic filings for 2026-27 patent expiries. Kakinada Unit 3 phase I will gradually begin production in FY25, with full benefits expected in 2 years. Management expects pricing to stabilize in coming quarters and maintains a double-digit growth outlook. Key risk: persistent pricing erosion in large-volume generics could pressure margins if volumes don't compensate.
डिविस लैब्स ने पहली तिमाही (Q1 FY25) में अच्छा प्रदर्शन किया। कंपनी की कुल कमाई ₹2,197 करोड़ रही, जो पिछले साल से 18% ज़्यादा है। मुनाफा ₹430 करोड़ रहा, जो 21% बढ़ा। कंपनी को खास तौर पर कस्टम सिंथेसिस (दूसरी कंपनियों के लिए दवा बनाना) से अच्छी कमाई हुई, जो 49% हिस्सेदारी रखता है और 40% बढ़ा। पुरानी दवाओं (जैसे नेप्रोक्सन) पर कीमत दबाव है, लेकिन जेनेरिक दवाओं की मांग स्थिर है। कंपनी नई दवाओं (पेप्टाइड्स, कंट्रास्ट मीडिया) पर काम कर रही है और 2026-27 में पेटेंट खत्म होने वाली दवाओं के लिए तैयारी कर रही है। काकीनाडा यूनिट 3 का पहला चरण इसी साल शुरू होगा, पूरा फायदा 2 साल में मिलेगा। प्रबंधन को उम्मीद है कि कीमतें स्थिर होंगी और कंपनी दोहरे अंकों में बढ़ती रहेगी। खतरा: बड़ी मात्रा वाली जेनेरिक दवाओं पर कीमत दबाव बना रहा तो मुनाफा कम हो सकता है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Pricing pressure in large-volume generics
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Generics to Custom Synthesis Mix
51:49
Custom synthesis share up ~40% YoY
Custom synthesis segment grew strongly, now nearly equal to generics in revenue contribution.
Exports to US and Europe
70%
Stable YoY
Majority of exports continue to be to regulated markets, indicating stable demand.
Capital Work in Progress (Kakinada)
INR 1,062 crore
Kakinada project accounts for INR 837 crore
Greenfield expansion progressing; phase I production to begin gradually in FY25.
Cash on Books
INR 4,229 crore
Strong liquidity position
Healthy cash reserves support future capex and dividend payout of INR 796 crore.
What Changed vs Last Quarter
NEW
Kakinada Unit 3 phase I production to begin gradually in FY25
The 200-acre phase I of the greenfield expansion will start production during FY2024-25, with regulatory approvals and customer filings taking 1-2 years for full commercialization.
NEW
New generic products to commercialize in FY26
Emerging generic products with DMF filings planned for completion in the next few months will be commercialized in FY2026, targeting patent expiries in 2025-27.
NEW
Maintenance capex of INR 250-300 crore for FY25
Management guided maintenance capex in the range of INR 250-300 crore for the current fiscal year.
UPDATED
Double-digit revenue growth expected for FY25
Management reiterated confidence in achieving double-digit growth for the full year, driven by both generics and custom synthesis.
DROPPED
Kakinada plant production to start Q2 FY25, commercialization by Q3 FY25
Phase I of Kakinada greenfield project will commence production in Q2 FY25, with commercial supplies expected by Q3 FY25 subject to regulatory approvals.
DROPPED
GLP-1 building block commercial benefits from 2025
Qualifications for GLP-1 building blocks with innovators are ongoing; commercial revenues expected from 2025.
NEW RISK
Pricing pressure in large-volume generics
Persistent price erosion in products like naproxen, gabapentin, and dextromethorphan may continue for 12-15 months due to channel destocking, impacting revenue growth.
NEW RISK
Red Sea logistics disruptions
Freight hikes and transit delays due to rerouting and vessel cancellations are increasing costs and requiring advance shipping schedules, which could impact margins.
NEW RISK
Dependence on custom synthesis project wins
While BIOSECURE Act opportunities are emerging, the timing and conversion of phase II/III molecules into commercial revenue remain uncertain and may take years.
NEW RISK
Nutraceutical segment stagnation
Nutraceutical revenue was flat YoY at INR 178 crore; management attributes it to quarterly lumpiness, but sustained weakness could weigh on overall growth.
RISK GONE
Red Sea crisis impacting freight costs and supply chain
Management noted a 30% spike in freight costs due to rerouting and war risk insurance, which could pressure margins in coming quarters.
RISK GONE
Generic pricing pressure may persist for 2-3 quarters
Management indicated that generic API pricing pressure is cyclical and may take 2-3 quarters to stabilize, potentially impacting near-term revenue.
RISK GONE
Regulatory approval delays for customer projects
Several custom synthesis and generic projects are awaiting FDA/EU approvals, which are outside Divi's control and could delay revenue recognition.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q3 FY24
Management expects double-digit revenue growth for FY25, driven by custom synthesis ramp-up and new generic launches.
Fast read
Guidance and risk preview
Management reiterated confidence in achieving double-digit growth for the full year, driven by both generics and custom synthesis.
Persistent price erosion in products like naproxen, gabapentin, and dextromethorphan may continue for 12-15 months due to channel destocking, impac...
View Risks →